University of Pennsylvania

Inovio Pharmaceuticals, Inc.

The Wistar Institute of Anatomy & Biology

The Wistar Institute

Other

Apollon, Inc.

Trustees of the University of Pennslyvania

Valorisation-recherche, Societe En Commandite

Bp Corporation North America Inc.

Colorado State University Research Foundation

Philadelphia Health and Education Corporation

Vgx Pharmaceuticals, Inc.

Institut De Recherches Cliniques De Montreal

Cargill Inc.

Drexel University

David B Weiner

Jian Yan

Karuppiah Muthumani

Niranjan Y Sardesai

Matthew P Morrow

William Valentine Williams

Mathura P Ramanathan

Bernadette Ferraro

Kar Muthumani

Velpandi Ayyavoo

Ruxandra Draghia-Akli

Ami Patel

Bin Wang

David Nathan Levy

Nyamekye Obeng-Adjei

Yosef Refaeli

Daniel Villarreal

Mamata Patel

Sundarasamy Mahalingam

Patricia A Brown

Amir S Khan

Douglas R Kern

Joo-Sung Yang

Mark I Greene

Toby Howard Richardson

Kenneth E Ugen

Michael Agadjanyan

Robert M Williams

Grace DeSantis

Paula M Hicks

Peter Luginbuhl

Steven John Gort

Lishan Zhao

Ellen Burke

Michele Kutzler

Devon Shedlock

Dominick J Laddy

Jewell Walters

Connie Jo Hansen

Kate Broderick

Fernando A Sanchez-Riera

Shaun Healey

Geoff Hazlewood

Anna Slager

Neil Cooch

David Blum

Christopher Solheid

Alexander Varvak

Brian J Brazeau

Mervyn L De Souza

Rodney A Bowling

Thomas Kieber-Emmons

Seleeke Flingai

Megan Wise

Donghui Zhang

Jeong-Im Sin

Elizabeth Duperret

Sarah Elliott

Richard A Carrano

Veronica Scott

Jeffrey A Cohen

Mark J Holterman

Rafick P Sekaly

Thanadavarayan Nagashunmugam

Andrew Y Choo

Jong J Kim

Alfredo Perales Puchalt

Jean D Boyer

Michael Madaio

Daniel Choo

Trevor R F Smith

Kimberly A Kraynyak

Krystle A Lang

Emma L Reuschel

Thomas Todaro

Kristine Chang

Thomas Woodward

Charles Hancock

Charles Reed

Jon Prigge

Lauren A Hirao

Emile Mohler

Geoffrey Ouma

Michael A Chattergoon

Mathew P Morrow

Natalie Hutnick

Adam Cohen

David Hokey

Sundarasama Mahalingham

Joan M Von Feldt

Scott Baliban

J Joseph Kim

Scott W Beaver

Arnold I Levinson

Hwai Chang

Sandra Calarota

Miguel Otero

Krystle A Lang-Kuhs

An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.

Vaccines against Zika virus

The present invention relates to compositions and methods for treating and/or preventing Canine Distemper Virus (CDV) in mammals susceptible to CDV.

Canine distemper vaccines and methods of treatment using the same

An aspect of the present invention is related to nucleic acid constructs capable of expressing at least one Nipah virus (NiV) antigen that elicits an immune response in a mammal against NiV virus, and methods of use thereof.

Vaccines against Nipah virus, and methods of using same

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Crimean-Congo hemorrhagic fever virus (CCHFV) antigens. Immunomodulatory methods and methods of inducing an immune response against CCHFV are disclosed. CCHFV glycoprotein immunogens are disclosed.

DNA vaccine against crimean-congo hemorrhagic fever virus (CCHFV)

The invention includes a vaccine comprising an antigen and IL-21. The invention also includes methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.

Vaccines having an antigen and interleukin-21 as an adjuvant

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.

consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensusglycoproteinimmunogens are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response againstare disclosed. Method of preventingand methods of treating individuals infected withare disclosed. Consensusproteins are disclosed.

Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets CTLA-4. The disclosure also provides a method of preventing and/or treating disease, such as cancer, in a subject using the composition of the invention.

DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer

Disclosed herein is a composition comprising a nucleic acid sequence encoding a Mayaro Virus antigen that elicits an immune response in a mammal. Also disclosed herein is a nucleic acid sequence encoding an anti-Mayaro Virus antibody, a fragment thereof, a variant thereof. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Mayaro virus infection in a subject using said composition and method of generation.

Mayaro virus consensus antigens, DNA antibody constructs for use against Mayaro virus, and combinations thereof

Provided herein is an immunogenic composition comprising a synthetic consensus antigen to chondroitin sulfate proteoglycan 4 (CSPG4) protein which is abundant in many cancers. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.

Optimized synthetic consensus immunogenic compositions targeting chondroitin sulfate proteoglycan 4 (CSPG4)

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an Ebola viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an Ebola virus infection in a subject using said composition and method of generation.

DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets PCSK9. The disclosure also provides a method of preventing and/or treating disease, such as cardiovascular disease or hypercholesterolemia, in a subject using the composition of the invention.

Nucleic acid monoclonal antibodies targeting PCSK9 and methods of use

Provided herein are sequences ofspp. liver stage exported proteins as well as expression constructs expressing the sequences. Also provided herein are methods for generating an immune response against malaria using the expression constructs provided herein.

Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections

Disclosed herein are compositions comprising structurally modified DNA encoded antibodies (DMAbs), methods of structurally modifying DMAbs, and methods of using structurally modified DMAbs.

Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies

Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.

Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom

Growing community of inventors

Merion, PA, United States of America

David B Weiner